Articles by Keyword for

Both Germany and France have taken Actos off the market because of an increased risk of getting bladder cancer. The US is taking no action. Global sales of Actos are in the vicinity of $5 billion annually. All three "glitazone" drugs for type 2 diabetes have a poor track record. Rezulin was taken off the market more than a decade ago because it caused...

  The Journal of the National Cancer Institute in August published an article showing that both Avandia and Actos increase bladder cancer by more than 400% compared to baseline incidence in diabetics. These drugs account for more than 20% of all drugs used to treat type 2 diabetes. Actos ranks 9th in the sales of all pharmaceutical drugs. This is remarkable...